Abstract
The treatment of venous thromboembolism (VTE), which consists of pulmonary embolism (PE) or deep vein thrombosis (DVT), can be complex. In recent years the introduction of novel pharmacologic treatments, as well as, increased use of catheter-directed thrombolysis, systemic intravenous thrombolysis, and surgical embolectomy interventions have been utilized either instead of or in addition to traditional VTE treatment with the hopes to improve outcomes. Traditional treatment options for VTE continue to be unfractionated heparin (UFH), low molecular weight heparin (LMWH), and oral vitamin K antagonists (warfarin).
As with any anticoagulant, there are challenges in selecting the most appropriate therapy based on individual patient factors, determining length of anticoagulation therapy, providing education, and monitoring outcomes. This chapter will focus on how the pharmacist can impact each of these challenges when treating VTE in either the inpatient or ambulatory settings.
Keywords
- Pulmonary Embolism
- Deep Vein Thrombosis
- Inferior Vena Cava
- International Normalize Ratio
- Insulin Glargine
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed. American college of chest physicians evidence based clinical practice guidelines. Chest 141:e419s–e494s
Dupras D, Bluhm J, Felty C, et al (2013) Institute for clinical systems improvement: venous thromboembolism diagnosis and treatment. Available via http://bit.ly/VTE0113. Accessed 10 Mar 2015
Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808
Agnelli G, Buller HR, Cohen A et al (2013) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368(8):699–708
Schulman S, Kearon C, Kakkar AK et al (2013) Extended use of dabigatran, warfarin or placebo in venous thromboembolism. N Engl J Med 368:709–718
Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352
The Hokusai-VTE Investigators (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406–1415
Buller HR, Prins MH, Lensing AW et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297
Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510
Spyropoulos AC, Lin J (2007) Direct medical cost of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 13(6):475–486
Mahan CE, Borrego ME, Woersching AL et al (2012) Venous thromboembolism: annualized United States models for total, hospital acquired and preventable costs utilizing long-term attack rates. Thromb Haemost 108:291–302
Grau E, Tenias JM, Real E et al (2001) Home treatment of deep vein thrombosis with low molecular weight heparin: long term incidence of recurrent venous thromboembolism. Am J Hematol 67:10–14
Ramacciotti E, Araujo GR, Lastoria S et al (2004) An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Thromb Res 114:149–153
Koopman MM, Prandoni P, Piovella F et al (1996) Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home. The Tasman Study Group. N Engl J Med 334:682–687
Piran S, Le Gal G, Wells PS et al (2013) Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis. Thromb Res 132:515–519
Erkens P, Gandara E, Wells PS et al (2012) Does the pulmonary embolism severity index accurately identify low risk patients eligible for outpatient treatment. Thromb Res 129:710–714
Aujesky D, Roy P, Verschuren F et al (2011) Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomized, non-inferiority trial. Lancet 378:41–48
Provias T, Dudzinski DM, Jaff MR et al (2014) The Massachusetts general hospital pulmonary embolism response team (MGH PERT): creation of a multidisciplinary program to improve care of patients with massive and submassive pulmonary embolism. Hosp Pract 42(1):31–37. doi:10.3810/hp.2014.02.1089
Kabrhel C, Jaff MR, Channick RN et al (2013) A multidisciplinary pulmonary embolism response team. Chest 144:1738–1739
Marano P, Cina G, Cotroneo AR et al (1996) Multidisciplinary approach to venous thromboembolism. Rays 21(3):481–499
Bates SM, Jaeschke R, Stevens SM et al (2012) Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed. American college of chest physicians evidence based clinical practice guidelines. Chest 141:e351s–e481s
Wells PS, Anderson DR, Rodger M et al (2000) Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increase the models utility with the SimpliRED D-dimer. Thromb Haemost 83(3):416–420
Wells PS, Anderson DR, Rodger M et al (2001) Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med 135(2):98–107
Wolf SJ, McCubbin TR, Feldhaus KM et al (2004) Prospective validation of Wells criteria in the evaluation of patients with suspected pulmonary embolism. Ann Emerg Med 44(5):503–510
Stein PD, Woodard PK, Weg JD et al (2007) Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II investigators. Radiology 242(1):15–21. doi:10.1148/radiol.2421060971
Van Belle A, Buller HR, Huisman MV et al (2006) Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 295(2):172–179. doi:10.1001/jama.295.2.172
Wells PS, Anderson DR, Bormanis J et al (1997) Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 350(9094):1795–1798
Kearon C, Julian JA, Newman TE et al (1998) Non-invasive diagnosis of deep vein thrombosis. Ann Intern Med 128:663–677
Carpenter JP, Holland GA, Baum RA et al (1993) Magnetic resonance venography for the detection of deep vein thrombosis: comparison with contrast venography and duplex Doppler ultrasonography. J Vasc Surg 18:734–741
Peterson DA, Kazerooni EA, Wakefield TW et al (2001) Computed tomography venography is specific but not sensitive for diagnosis of acute lower extremity deep vein thrombosis in patients with suspected pulmonary embolism. J Vasc Surg 34:798–804
Jongbloets LMM, Lensing AWA, Koopman MMW, Buller HR, ten Cate JW (1994) Limitations of real-time compression ultra-sound for the detection of asymptomatic deep-vein thrombosis in postoperative patients. Lancet 343:1142–1144
Heijboer H, Buller HR, Lensing A, Turpie A, Colly LP, ten Cate JW (1993) A comparison of real-time compression ultra-sonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med 329:1365–1369
Stein PD, Fowler SE, Goodman LR et al (2006) Multidetector computed tomography for acute pulmonary embolism. N Engl J Med 354(22):2317–2327. doi:10.1056/NEJMoa052367
Sostman HD, Stein PD, Gottschalk A et al (2008) Acute pulmonary embolism: sensitivity and specificity of ventilation-perfusion scintigraphy in PIOPED II study. Radiology 246(3):941–946
Miniati M, Monti S, Pratali L et al (2001) Value of transthoracic echocardiography in the diagnosis of pulmonary embolism: results of a prospective study in unselected patients. Am J Med 110(7):528–535
Stein PD, Chenevert TL, Fowler SE et al (2010) Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med 152(7):434–443
Product Information: heparin sodium injection (2014) Pfizer, Kirkland
Smith SB, Geske JB, Maguire JM et al (2010) Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest 137(6):1382–1390
Hatjipetrou A, Anyfantakis D, Kastanakis M (2015) Rectus sheath hematoma: a review of the literature. Int J Surg 13:267–271
Enoxaparin [package insert] (2013) Sanofi-Aventis US LLC, Bridgewater
Dalteparin [package insert] (2014) Pfizer, Kirkland
Tinzaparin [package insert] (2010) LEO Pharmaceuticals Company, Parsipany
Nadroparin [package insert] (2011) GlaxoSmithKline Inc, Mississauga
Ageno W, Gallus AS, Wittkowsky A et al (2012) Oral anticoagulant therapy, antithrombotic therapy and prevention of thrombosis, 9th ed. American college of chest physicians evidence based clinical practice guidelines. Chest 141:e44s–e88s
Pawloski SJ, Kersh PL (1992) Therapeutic heparin monitoring service in a small community hospital. Hosp Pharm 27(8):703–706
Saya FG, Coleman LT, Martinoff JT (1985) Pharmacist-directed heparin therapy using a standard dosing and monitoring protocol. Am J Hosp Pharm 42(9):1965–1969
Bond CA, Raehl CL (2004) Pharmacist provided anticoagulation management in United States hospitals: death rates, length of stay, medicare charges, bleeding complications and transfusions. Pharmacotherapy 24:953–963
Price C, Colodny L (2000) Partnering with nurses to manage heparin therapy with a weight based protocol. Am J Health Syst Pharm 57(2):110–112, 115–116
Dobesh PP, Trujillo TC, Finks SW (2013) Role of the pharmacist in achieving performance measures to improve the prevention and treatment of venous thromboembolism. Pharmacotherapy 33(6):650–664
Dawson NL, Porter IE, Klipa D et al (2012) Inpatient warfarin management: pharmacist management using a detailed dosing protocol. J Thromb Thrombolysis 33:178–184
Fowler S, Gulseth MP, Renier C et al (2012) Inpatient warfarin: experience with a pharmacist-led anticoagulation management service in a tertiary care medical center. Am J Health Syst Pharm 69:44–48
Strieff MB (2015) Predicting the risk of recurrent venous thromboembolism (VTE). J Thromb Thrombolysis 39:353–366
Iorio A, Kearon C, Filippucci E et al (2010) Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 170:1710–1716
Douketis J, Tosetto A, Marcucci M et al (2011) Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 342:d813
McRae S, Tran H, Schulman S et al (2006) Effect on patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 368:371–378
Bates SM, Greer IA, Middeldorp S et al (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed. American college of chest physicians evidence based clinical practice guidelines. Chest 141:e691s–e736s
Prandoni P, Lensing AW, Picciolo A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484–3488
Le Gal G, Righini M, Roy PM et al (2006) Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 144:165–171
Klok FA, Mos I, Nijkeuter M et al (2008) Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med 168(19):2131–2136
Rodger MA, Kahn SR, Wells PS et al (2008) Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 179:417–426
Tosetto A, Iorio A, Marcucci M et al (2012) Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 10:1019–1025. See comment in PubMed Commons below
Louzada ML, Carrier M, Lazo-Langner A et al (2012) Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 126:448–454
Den Exter PL, Kooiman J, Huisman MV (2013) Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis. J Thromb Haemost 11:998–1000
Leger S, Allenet B, Pichot O et al (2004) Impact of an education program on patient behavior favoring prevention of drug-related adverse events: a pilot study in patients receiving oral anticoagulants for thromboembolic venous disease. J Mal Vasc 29(3):152–158
Moreland CJ, Kravitz RL, Paterniti DA et al (2013) Anticoagulation education: do patients understand potential medication-related emergencies? Jt Comm J Qual Patient Saf 39(1):22–31
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Rose, A.E. (2015). Treatment of Venous Thromboembolism. In: Rose, A. (eds) Anticoagulation Management. Adis, Cham. https://doi.org/10.1007/978-3-319-22602-6_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-22602-6_7
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-22601-9
Online ISBN: 978-3-319-22602-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)